medRxiv PreprintsInternational16 November 2026
Sublingual Buprenorphine Is Associated with Increased Caries Experience and Altered Oral Microbial and Salivary Risk Factors
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Background: Sublingual buprenorphine (SLB) is commonly prescribed to treat opioid use disorder. Pharmacoepidemiologic studies suggest an association between SLB and severe dental caries, yet clinical investigations are lacking. Objective: To assess caries experience and caries-related risk factors among patients taking SLB. Methods: This pilot cross-sectional study enrolled 11 subjects taking SLB films, 10 taking SLB tablets, and 10 age- and sex-matched controls. Demographic, medical, dental, and behavioral data were collected. Caries examinations were performed. Salivary pH, buffering capacit
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.